Aesica Joins Forces with Britest
News Feb 15, 2013
Aesica has announced that it will be joining Britest in a collaboration where members share knowledge and risk in defining innovative solutions to key manufacturing challenges.
Britest has already engaged with 22 leading global chemical and pharmaceutical organizations together with a number of academic organizations.
The partnerships are designed to utilize and further develop Britest’s innovative tools and methodologies to support whole process understanding.
In particular, Aesica will be utilizing Britest’s expertise to identify new approaches and technologies that drive major improvements in API manufacturing processes.
The Aesica Innovation Board (AIB) aims to identify and commercialize new innovative technologies that help to bridge the growing R&D gap though industry and academic collaborations.
Joining Britest will increase the AIB’s access to applicable, relevant technologies and strengthen the organizations relationships throughout the industry.
Dr Barrie Rhodes, Aesica Director of Technology Development said: “At Aesica we aspire to develop and implement new technologies and improve processes to support business growth. Following the successful demonstration of the Britest approach on a key Active Pharmaceutical Ingredient process at our Cramlington site, we are now looking forward to engaging fully in the Britest collaboration and implementing the Britest approach across a range of processes.”
Sue Fleet, Britest CEO said: “I am delighted to welcome Aesica Pharmaceuticals as our latest company member. With a clear focus on innovation and collaboration, we look forward to supporting Barrie and his colleagues at Aesica in driving innovative thinking and deriving full value from their membership of Britest.”
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.